Intradigm

For the six-month period ended June 30, Silence's net loss rose to ₤7.05 million ($11 million) from ₤3.57 million in the year-ago period.

Silence said that as a result of the consolidation, it has laid off about 20 staffers, primarily in research and development.

The companies touted the financial benefits of the transaction, but it appears that the establishment of a broad drug-delivery portfolio attractive to prospective big pharma partners was the primary driver of the deal.

The change follows a number of false starts RXi has made in regard to its pipeline, as well as the firm’s failure to meet previously stated partnering goals. But RXi is not alone in this respect, and management changeups in troubled times have been par for the course among RNAi drug shops.

While most companies working in the RNAi drugs field have been able to secure the money needed to maintain operations, a number of players in the space have bowed out under unfavorable circumstances.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.